Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H32O2 |
Molecular Weight | 364.5204 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(OC5CCCC5)C=C4
InChI
InChIKey=PWZUUYSISTUNDW-VAFBSOEGSA-N
InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB04575
Sources: http://www.drugbank.ca/drugs/DB04575
Quinestrol is a synthetic estrogen that is effective in hormone replacement therapy. It is a 3-cyclopentyl ether of ethynyl estradiol. After gastrointestinal absorption, it is stored in adipose tissue, where it is slowly released and metabolized in the liver to its active form, ethinyl estradiol. Quinestrol has found limited use in suppressing lactation in postpartum women and, in combination with synthetic progestogens, as contraceptive therapy, although additional studies are needed for both applications. Estrogens diffuse into their target cells and interact with a protein receptor (the estrogen receptor). Estrogen interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093866 Sources: http://www.drugbank.ca/drugs/DB04575 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ESTROVIS Approved UseQuinestrol |
|||
Palliative | Unknown Approved UseQuinestrol |
|||
Palliative | Unknown Approved UseQuinestrol |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of different nylestriol/levonorgestrel dosages on bone metabolism in female Sprague-Dawley rats with retinoic acid-induced osteoporosis. | 2003 Feb |
|
[Compound nylestriol tablet to prevent bone loss in osteoporotic rats]. | 2004 Aug |
|
[Effects of long-term replacement therapy of compound nylestriol tablet or low-dose 17 beta-estradiol on the expression of nerve growth factor in OVX rat hippocampal formation]. | 2004 Oct |
|
Antiosteoporotic activity of Er-Xian Decoction, a traditional Chinese herbal formula, in ovariectomized rats. | 2006 Nov 3 |
|
Anti-fertility effect of levonorgestrel and quinestrol in Brandt's voles (Lasiopodomys brandtii). | 2007 Dec |
|
The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. | 2007 Mar |
|
Once-a-month contraceptive pills in China: a review of available evidence. | 2007 May |
|
[Relationship between hormone therapy in women with ovarian malignancy and prognosis]. | 2008 Nov |
|
Antiosteoporotic activity of icariin in ovariectomized rats. | 2009 Apr |
|
[Effects of pilose antler and antler glue on osteoporosis of ovariectomized rats]. | 2009 Feb |
|
Treatments for suppression of lactation. | 2009 Jan 21 |
|
[Effect of nylestriol and levonorgestrel on the expression of estrogen receptor subtypes in human osteosarcoma MG-63 cell lines]. | 2010 Dec |
|
Low-dose hormone therapy in postmenopausal women in China. | 2010 Dec |
|
Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. | 2010 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/452871
1 mg of quinestrol in a one-tablet dose once a month
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2181
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QUINESTROL
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
m9441
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
2342
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
SUB10211MIG
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
9046
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
759637
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
7097
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
152-43-2
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
DTXSID6046553
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
8716
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
C66500
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201165
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
205-803-1
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
1612
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
D011800
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
DB04575
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
9066
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000080276
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY | |||
|
JR0N7XD5GZ
Created by
admin on Fri Dec 15 15:01:28 GMT 2023 , Edited by admin on Fri Dec 15 15:01:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY